Title: Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia-inducible factor-1α in colorectal cancer

Authors: Chao Fang1, Lei Dai2, Cun Wang1, Chuanwen Fan1, Yongyang Yu1, Lie Yang1, Hongxin Deng2*, Zongguang Zhou1*

Affiliation:
1. Institute of Digestive Surgery, Sichuan University, and Department of Gastrointestinal Surgery, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, P.R. China.
2. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, P.R. China

Correspondence:
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/1878-0261.13044

Molecular Oncology (2020) © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
SCG2 impairs tumor growth and angiogenesis via HIF-1α

Keywords:
Colorectal cancer, Secretogranin II, Angiogenesis, Hypoxia-inducible factor, Vascular endothelial growth factor

Abbreviations
CRC, colorectal cancer; SCG2, secretogranin II; VEGF, vascular endothelial growth factor; HIF, hypoxia-inducible factor; VHL, von Hippel-Lindau; HIEC, human intestinal epithelial cell; HVECs, human umbilical vein endothelial cells; ELISA, enzyme-linked immunosorbent assay; IHC, Immunohistochemistry;
Abstract

Distant metastasis is a major cause of death in patients with colorectal cancer (CRC), but the management of advanced and metastatic CRC still remains problematic due to the distinct molecular alterations during tumor progression. Tumor angiogenesis is a key step in tumor growth, invasion, and metastasis. However, the signaling pathways involved in angiogenesis are poorly understood. The results of the present study showed that secretogranin II (SCG2) was significantly downregulated in malignant CRC tissues and higher expression of SCG2 was correlated with longer disease-free survival and overall survival of CRC patients. The results of an animal study showed that ectopic expression of SCG2 significantly inhibited CRC tumor growth by disrupting angiogenesis. Furthermore, the inhibition of expression of vascular endothelial growth factor (VEGF) by SCG2 and rescue of VEGF efficiently blocked SCG2-induced inhibition of angiogenesis. Investigations into the underlying mechanism suggested that SCG2 promoted degradation of hypoxia-inducible factor (HIF)-1α by interacting with the von Hippel-Lindau (VHL) tumor suppressor in CRC cells. Blocking of degradation of HIF-1α efficiently attenuated...
the SCG2-mediated decrease in expression of VEGF in CRC cells. Collectively, these results demonstrated that treatment with SCG2 efficiently inhibited CRC tumor growth by disrupting the activities of HIF-1α/VEGF, thereby clarifying the anti-tumor and anti-angiogenesis roles of SCG2 in CRC, while providing a novel therapeutic target and a potential prognostic marker of disease progression.

1. Introduction

Colorectal cancer (CRC) is the third of the most commonly diagnosed cancers and the fourth most common causes of cancer-related death worldwide [1]. Owing to the introduction and dissemination of screening tests, the identification of risk factors, and improvements in treatment regimens, the oncologic outcomes of CRC patients have been greatly improved over the past few decades [2-4]. However, distant metastasis which occurs in more than 60% of CRC cases during the disease progression is the primary cause of the death of CRC patients [5-7]. Hence, tumor metastasis is among the most critical prognostic factors for CRC and a major obstacle to successful treatment [7, 1]. The management of advanced and metastatic CRC still remains problematic due to the distinct molecular alterations during the tumor progression [8, 9]. Thus, a better understanding of the molecular mechanisms underlying CRC disease progression and metastasis is needed to improve therapeutic strategies and outcomes.

The disease progression and distant metastasis of solid tumors depend on the formation of
tumor-related vessels to obtain the necessary nutrients and oxygen [10]. More specifically, angiogenesis and vasculogenesis are crucial for tumor growth, invasion, and metastasis [10]. Angiogenesis refers the “sprouting” of new blood vessels from existing vessels, while vasculogenesis refers to the regeneration of endothelial cells from endothelial progenitor cells derived from bone marrow [11, 12]. The dependence of solid tumors on the formation of new vessels has led to the development and application of various anti-angiogenesis agents, such as bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), which has improved the oncologic outcome of patients with metastatic and advanced CRC [13]. However, patients with some specific genetic types are at risk of therapeutic resistance and rapid disease progression [14, 15]. Thus, it is necessary to identify the signaling networks associated with angiogenesis and vasculogenesis to elucidate the molecular mechanisms underlying tumor invasion and metastasis.

Secretogranin II (SCG2), a key AP-1-regulated member of the granin family, is a neuroendocrine protein that regulates the biogenesis of secretory granules involved in hormonal peptide sorting [16], mediates neuronal differentiation, and protects neuroblastoma cells from nitric oxide-induced apoptosis. SCG2 is cooperatively activated by glutamate-dopamine hippocampal neurons as a potential regulator of food intake and non-chronic body weight change by interacting with secretogranin III and accumulating appetite-related hormones into secretory granules [17]. Various studies have demonstrated pro-angiogenesis roles of SCG2 in the process of wound injury [18] and ovulation [19] based on the direct effects in endothelial cells. In addition, SCG2 has been implicated as a candidate tumor suppressor in several tumors [20]. SCG2 expression has also been associated with the survival outcome of CRC patients [21, 22]. However, the functional significance of SCG2 in CRC still remains unclear.

Therefore, the aim of the present study was to investigate the expression and function of SCG2 in CRC. The protein expression profile of SCG2 in CRC was determined in 270 pairs of malignant and adjacent normal tissues, followed by correlation analysis of the prognostic outcomes of CRC patients. The function of SCG2 was determined with the use of a mouse xenograft model and the underlying mechanism was investigated by RNA sequencing, co-immunoprecipitation and other technologies. Taken together, the study indicated a role of SCG2 in the disease progression of CRC, thereby providing a potential therapeutic target and a predictor of the survival of CRC patients.
2. Materials and methods

2.1. Clinical sample

This study enrolled CRC patients at the Department of gastrointestinal Surgery, West China Hospital, Sichuan University. All the tumor and paired adjacent normal tissues were collected from CRC patients undergoing curative resection between 2013 and 2014. All the frozen tissues were fixed with 4% paraformaldehyde, embedded with paraffin and cut into 4 μm slides for H&E staining. The histopathological evaluation was performed by one experienced pathologist and reviewed by other two pathologists. The qualified samples were used for tissue microarray by Outdo Biotech (Shanghai, China), and the tissue microarray named as HXCRC (HuaXi Colorectal Cancer) cohort. All patients were suggested for postoperative treatment and scheduled for periodic follow-ups as recommend by NCCN guidelines. The disease-free survive and overall survive was recorded by arranging follow-up in the next five years after surgery. The study methodologies conformed to the standards set by the Declaration of Helsinki. Informed consent was collected from all patients and the experiments were approved by the Research Ethics Committee of West China Hospital, Sichuan University (Number: 2017(169)).

2.2. Cell culture and treatment

Human CRC cells SW620, SW480, RKO, HCT116, LoVo, DLD-1, Caco-2, HT-29 and normal human intestinal epithelial cell (HIEC) were purchased from American of Type Culture Collection (ATCC, Manassas, VA, USA). SW620, SW480, RKO, HCT116, DLD-1, Caco-2, HT-29 and normal human intestinal epithelial cell (HIEC) were cultured in DMEM (Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Thermo Fisher Scientific, Inc.) and LoVo cells were cultured in Minimum Essential Medium (Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Thermo Fisher Scientific, Inc.). Human umbilical vein endothelial cells (HUVECs) were obtained from human umbilical veins as previously described and cultured in EGM medium (Merck Millipore, MA, USA). All cells were incubated at 37°C with 5% CO₂. Lentivirus based SCG2 overexpression system and empty vector control were purchased from Gene Pharma (Shanghai, China) and used to infect SW620 and RKO cells (MOI=20). At 24 hours post lentivirus infection, the culture supernatant were removed and new medium containing 2 mg/ml puromycin was added to select stable infected cells.
2.3. Western blotting

SW620 and RKO cells were collected and lysed in RIPA lysis buffer (Beyotime, Beijing, China) containing protease inhibitor cocktail (Merck Millipore, MA, USA). After centrifugation for 12,000 g at 4°C for 15 minutes, the protein was collected for concentration determination by BCA assay (Thermo Fisher Scientific, Inc.). A total of 10 µg proteins was loaded per lane, separated by 10% and 7.5% SDS-PAGE and transferred to 0.45-µm polyvinylidene fluoride membranes (Merck Millipore, MA, USA). After blocking with TBS-Tween-20 (0.1% Tween-20) containing 0.5% non-fat milk, the membranes were incubated with primary antibodies at 4°C overnight. Following incubation with anti-mouse IgG or anti-rabbit IgG secondary antibodies at 37°C for 1 h, protein expression was detected by chemiluminescence with a kit from Merck Millipore.

2.4. Animal study

Female BALB/c nude mice (5-6 weeks old) were purchased from HFKbio (Beijing, China) and allowed to acclimate for 1 week before use. All mice were given free access to food and water in a specific pathogen free condition. SW620 and RKO cells that were stably infected with lenti-SCG2 or lenti-control (5 × 10⁶ cells) were injected into the flank of mice to establish a subcutaneous cancer model. Tumor length and width were measured by vernier caliper every three days and the tumor volume was calculated as length × width² × 0.52. At 22 days post cell injection, mice were sacrificed and tumors were collected, weighed and used for further analysis. For Matrigel plug assay, 2 × 10⁶ cells embedded in 100 µl Matrigel were injected into the flank of mice. Seven days later, the Matrigel plug were collected and used for further analysis. Human SCG2 protein and control IgG were purchased from Proteintech (Wuhan, China) and were injected into the tumors at 8, 10 and 12 days post SW620 cell injection. All of the animal study was approved by the Institutional Animal Care and Use Committees of Sichuan University.

2.5. Histological staining

Tumor tissue sections (5-µm thick) and CRC tissue microarray were deparaffinized with xylene, rehydrated in a graded ethanol series, and washed in ultrapure water. After autoclaving at 120°C for 5 minutes for antigen retrieval with citrate repair buffer (pH 6.0, Origene), the sections were incubated in 3%H₂O₂ and 5% goat serum at room temperature for 15 minutes, and incubated with primary antibodies against SCG2 (LS-B10869, Life Span Biosciences), HIF-1α (ab51608, abcam), VEGF (ab150375, abcam) and CD31 (ab28364, abcam) overnight at 4°C. For
immunohistochemical staining, the sections were incubated with secondary antibodies (Zsbio, Beijing, China) and HRP-conjugated streptomycin solution (Zsbio) for 30 minutes at 37°C and stained with 3, 3-diaminobenzidine (Maixin, Fuzhou, China). For immunofluorescence staining, the sections were incubated with Texas Red-conjugated secondary antibody (Thermo Fisher Scientific, Inc.) at 37°C for 1 hour and cell nucleus were stained with DAPI (Thermo Fisher Scientific, Inc.). The pictures were taken by BX 51 microscope (Olympus, Tokyo, Japan).

2.6. HUVEC tube formation assay and invasion assay

For tube formation, 2 × 10^4 HUVECs in 100 µl of conditional medium (cell culture supernatant) were seeded into a 96-well containing 50 µl Matrigel (Merck Millipore, MA, USA) and incubated at 37°C with 5% CO₂ for 4 hours. The tube photos were taken by inverted microscope and branch points in each frame were counted. For invasion assay, 50 µl Matrigel (Merck Millipore, MA, USA) which was diluted with DMEM (1:5 dilution) was added into transwell insert (8.0 µm, Corning, Kennebunk, ME, USA) and 2 × 10^4 HUVECs in 100 µl of conditional medium (cell culture supernatant) were seeded into the coated transwell. After 24 h of incubation, non-invaded cells were removed with a cotton swab from the upper part of the transwell and inserts were fixed with 4% paraformaldehyde for 15 minutes at room temperature. The inserts were stained in 500 µl of 0.03% crystal violet solution (Beyotime, Beijing, China) and sheeted with neutral balsam (Beyotime, Beijing, China). Five pictures were taken for each insert and number of invaded cells in each frame was counted.

2.7. RNA extraction and analysis

SW620 and RKO cells and tumors were collected for RNA extraction using Trizol (Invitrogen), following to the instructions of manufacturer. RNA concentration was measured by ND2000 (Thermo Fisher Scientific, Inc.) and their quality and quantity were determined using a NanoPhotometer® spectrophotometer (Implen, Munich, Germany), RNA Nano 6000 Assay Kit and the Bioanalyzer 2100 system (Agilent, Santa Clara, CA, USA). For quantitative RT-PCR, 1 µg RNA was converted to cDNA using PrimeScript RT reagent Kit with gDNA Eraser (RR047B, Tokyo, Japan). TB green Premix EX TaqII (RR820A, Tokyo, Japan) was used for quantitative PCR reactions in CF96 (Bio-Rad). Relative VEGF expression was determined by 2^-DDCt, where Ct is the mean threshold cycle difference after normalization to GAPDH. RNA sequencing was performed by Chengdu Basebiotech Co., Ltd (Chengdu, China) as previous study indicated [23].
Significantly differentially expressed mRNAs were screened based on absolute value of log2 (fold change) >=1, at a P value < 0.05. KEGG pathway enrichment was analyzed using the “ggplot2” R package and the online biological tool, KOBAS 3.0 (http://kobas.cbi.pku.edu.cn).

2.8. Enzyme-Linked Immunosorbent assay (ELISA)

The cell culture supernatant of SW620 and RKO cells were collected and stored in -80°C condition. VEGF expression was determined by ELISA kit according the instruction of manufacturers.

2.9. Co-immunoprecipitation

SW620 and RKO cells were collected and lysed with RIPA lysis buffer (Beyotime, Beijing, China) containing 1% protease inhibitor cocktail (Merck Millipore, MA, USA). After centrifugation for 12,000 g at 4°C for 15 minutes, the protein was collected for concentration determination by BCA assay (Thermo Fisher Scientific, Inc.). Co-immunoprecipitation was performed according to the instructions of PureProteome™ Protein A and Protein G MagneticBeads (Merck Millipore, MA, USA). Total 500 µl protein was added for the direct immunoprecipitation and 10 µl primary antibodies against SCG2 or VHL was added for immunoprecipitating the specific protein. The immunoprecipitated products were collected for western blotting.

2.10. Statistical analysis

Continuous variables are presented as the mean ± standard deviation. Explorative comparisons of groups were using the t-test for normally distributed data and the Kruskal-Wallis test or the Mann-Whitney U test for non-normally distributed data. The Pearson’s χ² test was used to perform the distribution of nominal- or ordinal-scaled variables. The Kaplan-Meier method and the log-rank (Mantel-Cox) test were used to investigate the time-dependent survival probabilities to compare different subgroups of CRC patients. All statistical tests were two-sided and a probability (p) value of < 0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 22.0. (IBM corporation, Armonk, NY, USA).

3. Results
3.1. Downregulation of SCG2 is correlated with poor prognosis of CRC patients

Immunohistochemistry (IHC) staining was employed to determine the expression patterns of SCG2 in 270 CRC tissues and 115 normal intestinal tissues. The results revealed that SCG2 was mainly expressed in the cytoplasm of normal intestinal epithelial cells with relatively fewer SCG2-positive cells in malignant CRC tissues (Figure 1A). Furthermore, SCG2 was significantly downregulated in malignant CRC tissues as compared with normal tissues (Figure 1B). In accordance with the expression data retrieved from TCGA-COAD database, SCG2 mRNA was significantly downregulated in malignant CRC tissues (Figure 1C). The patients in the HXCRC cohort were further divided into low and high SCG2 expression achieved longer disease-free and overall survival (Figure 1D and 1E). Collectively, these results demonstrated that downregulation of SCG2 is correlated with a poor prognosis of CRC patients.

3.2. SCG2 impairs CRC tumor growth

A lentivirus-based SCG2 overexpression system was employed to investigate the potential function of SCG2 in CRC. As shown in figure 2A, SCG2 expression was decreased in most CRC cell lines, with the exception of Caco-2 cells. After stable infection with lenti-SCG2, ectopic expression of SCG2 was demonstrated in SW620-SCG2 and RKO-SCG2 cells (Figure 2B). Further IHC staining also indicated that SCG2 was significantly upregulated in SW620-SCG2 tumors (Figure 2C). In the subcutaneous xenograft model ectopic expression of SCG2 dramatically inhibited the growth of SW620 tumor cells by 73.0% in tumor volume as compared with control cells (293.1 ± 125.6 Vs 1086.4 ± 94.8 mm³, respectively, Figure 2D and 2E) and by 72.7% in tumor weight (0.27 ± 0.13 Vs 0.99 ± 0.10 g, respectively, Figure 2F). Similar inhibition was also confirmed in the growth of RKO tumor cells in mice as compared with the controls by volume (267.2 ± 122.0 Vs 1275.9 ± 241.8 mm³, respectively, Figure 2G and 2H) and weight (0.27 ± 0.13 Vs 1.20 ± 0.10 g, respectively, Figure 2I). These results demonstrated the anti-tumor effects of SCG2 in CRC.

3.3. SCG2 inhibits angiogenesis in CRC

Next, the potential regulatory role of SCG2 in tumor angiogenesis was investigated by IHC staining of CD31. As shown in figure 3A, there were fewer CD31-positive cells in the SW620-SCG2 group than the SW620-Ctrl group. Further analysis confirmed the inhibition of vessel density (Figure 3B) and vessel area (Figure 3C) by SCG2 in SW620 tumors. Similar results
were also demonstrated in RKO tumors (Figure 3D), as evidenced by significant inhibition of vessel density and area (Figure 3E and 3F, respectively). Furthermore, the results of the Matrigel-based plug assay showed that ectopic SCG2 expression significantly inhibited angiogenesis in the SW620-SCG2 group, as compared with the SW620-Ctrl group (Figure 3 G-I). Cell culture supernatant was collected for a HUVEC-based tube formation assay and invasion assay. As shown in Figure 3J, the supernatant of the SW620-SCG2 cell culture significantly inhibited tube formation of HUVECs. Meanwhile, less tube formation was observed in the HUVECs treated with RKO-SCG2 conditioned medium (Figure 3H). The results of the HUVECs-based invasion assay showed that the supernatant of the SW620-SCG2 and RKO-SCG2 cell cultures also dramatically decreased the invasion ability of HUVECs (Figure 3L and 3M). Collectively, ectopic expression SCG2 in CRC cells significantly inhibited tumor angiogenesis.

3.4. SCG2 inhibits angiogenesis via downregulating expression of VEGF

To investigate the molecular mechanisms underlying inhibition of tumor angiogenesis by SCG2 in CRC, mRNA sequencing was employed to determine the expression profiles of coding RNA in SW620 tumors. As shown in Figure 4A, 738 genes were downregulated and 24 genes were upregulated in SW620-SCG2 tumors, as compared with SW620-Ctrl tumors. KEGG analysis indicated that the deregulated genes in the VEGF signaling pathway played crucial roles in angiogenesis (Figure 4B). Furthermore, the qPCR results confirmed the inhibition of VEGF-165 by SCG2 in SW620 and RKO tumors (Figure 4C). Also, fewer VEGF-positive cells were observed in SW620-SCG2 tumors (Figure 4D) and ectopic expression of SCG2 inhibited transcription of VEGF mRNA (Figure 4E), resulting in lower expression of intracellular and excretive VEGF protein (Figure 4F and 4G, respectively). To determine whether VEGF plays a crucial role in the inhibition of tumor angiogenesis by SCG2, a HUVEC-related assay was performed after rescuing expression of VEGF in the supernatant of SW620-SCG2 cells. The results revealed that rescuing VEGF expression efficiently blocked SCG2-mediated inhibition of HUVEC-related tube formation (Figure 4H) and invasion (Figure 4I). Collectively, these results demonstrated that SCG2 inhibited tumor angiogenesis via decreasing expression of VEGF in CRC cells.

3.5. SCG2 promotes degradation of HIF-1α via binding to VHL

The expression of VEGF was inhibited by SCG2 at the mRNA and protein levels, indicating that
SCG2 inhibits expression of VEGF at the transcriptional level. However, SCG2 is a cytoplasmic protein. Thus, we speculated that SCG2 may inhibit the transcription of VEGF by regulating the expression of transcription factors, such as HIF-1. The results indicated that ectopic SCG2 expression inhibited the expression of HIF-1α, but had no significant effect on HIF-1β (Figure 5A and S1A). Meanwhile, the expression of hydroxy-HIF-1α and VHL was not regulated by SCG2 in SW620 and RKO cells (Figure 5B). Inhibition of protease activity by MG132 blocked SCG2-mediated inhibition of HIF-1α expression in CRC cells (Figure 5C), indicating that SCG2 promotes degradation of HIF-1α. The results of the co-immunoprecipitation assay suggested that SCG2 interacted with VHL and HIF-1α in CRC cells (Figure 5D and S1B-E). As compared with the SW620 Ctrl tumors, the SW620-SCG2 tumors contained fewer HIF-1α-positive cells (Figure 5E). Treatment of SW620-Ctrl and SW620-SCG2 cells with DMOG, an activator of HIF-1α, attenuated SCG2-mediated inhibition of VEGF expression in SW620 and RKO cells (Figure 5F and 5G). These results suggested that SCG2 inhibited VEGF expression by promoting interactions with VHL and degradation of HIF-1α.

3.6. Inverse correlation between SCG2 and HIF-1α/VEGF in CRC tissues

Based on the negative regulatory role of SCG2, the potential correlation with HIF-1α/VEGF expression in CRC tissues was investigated. IHC staining was employed to determine the expression profiles of SCG2, HIF-1α and VEGF expression in 45 malignant CRC tissues by analyzing the percentage of positive cells in each specimen. The results revealed high expression of HIF-1α and VEGF in specimens with low SCG2 expression and low expression of HIF-1α and VEGF in specimens with high SCG2 expression (Figure 6A). Correlation analysis indicated that in CRC tumor tissues, SCG2 expression was inversely correlated with HIF-1α expression (Figure 6B, r = -0.6229) as well as VEGF expression (Figure 6C, r = -0.6321). These results confirmed an inverse correlation between SCG2 and HIF-1α/VEGF expression in CRC tumor tissues.

3.7. SCG2 protein inhibits CRC tumor growth in mice

To determine the potential therapeutic effect of SCG2 on CRC tumor growth, the tumors were treated with SCG2 protein at 8, 10 and 12 days post-injection of SW620 cells (Figure 7A). The results indicated that treatment with the SCG2 protein dramatically inhibited SW620 tumor growth as compared to the controls (IgG) by 64.7% in tumor volume (419.6 ± 91.0 Vs 1190.2 ± 163.7 mm³, respectively, Figure 7B and 7C) and by 64.3% in tumor weight (0.38 ± 0.05 Vs 1.08 ± 0.12 mm³, respectively, Figure 7B and 7C).
g, respectively, Figure 7D). The IHC staining results revealed that treatment with SCG2 protein increased the number of SCG2-positive cells in SW620 tumors (Figure 7E), accompanied with inhibition of HIF-1α (Figure 7F) and VEGF (Figure 7G). These results demonstrated the therapeutic effect of the SCG2 protein in CRC.

4. Discussion

Tumor metastasis is a multistage process in which malignant cells disseminate from the primary tumor and colonize distant organs and/or nodes. During the metastasis process, angiogenesis and vasculogenesis are essential and critical steps for the formation of tumor-related vessels. Thus, it is increasingly important to understand the biology of angiogenesis and vasculogenesis in different types of cancers. SCG2 is a neuroendocrine protein that is diffusely expressed in tissues of the prostate, pancreas, and gastrointestinal tract, while SCG2 expression is relatively high in normal tissues. SCG2 has been implicated as a proangiogenesis factor in wound injury and ovulation. However, given the tissue specificity, the role of SCG2 likely differs among different tumor types. Analysis of clinical samples demonstrated that SCG2 was downregulated in CRC tumor tissues and high SCG2 expression was correlated with a good prognosis of CRC patients. Ectopic SCG2 expression significantly inhibited CRC tumor growth by disrupting tumor angiogenesis. Further results confirmed that the inhibition of VEGF expression by SCG2 inhibited angiogenesis in CRC tumors and also revealed that SCG2 interacted with VHL to promote VHL-dependent degradation of HIF-1α and block degradation of HIF-1α, which attenuated the SCG2-mediated decreased expression of VEGF. Taken together, these findings indicated that SCG2 had anti-tumor and anti-angiogenesis roles in CRC during disease progression.

SCG2 is widely expressed in diverse organs and tissues, and deregulated in various cancers [24]. The results of the present study revealed that expression of SCG2 was significantly downregulated at both protein and mRNA levels in malignant CRC tissues, but highly expressed in paired adjacent normal tissues. Some previous studies have reported significantly poorer survival of CRC patients with high expression signatures of five-genes, including SCG2, as compared to low-risk patients [22]. The expression of stroma-related SCG2 was also significantly associated with poorer survival of CRC patients [21]. In the present study, SCG2 protein expression was determined in 270 malignant tissues of CRC patients that were divided into two groups based on expression levels of SCG2 protein in tumor cells, but not in stromal cells. Prognosis analysis indicated that higher expression of SCG2 in tumor cells was correlated with
longer disease-free and overall survival, which is inconsistent with the results of previous studies [21, 22]. This discrepancy may have resulted from differences in the analytical approaches. Specifically, in the present study expression of SCG2 protein was quantified in tumor cells, while in the cited previous studies. Expression was measured in total cells. Collectively, the results of the present study suggested that expression of SCG2 protein in tumor cells was a positive prognostic predictor of CRC patients.

SCG2, as a key AP-1-regulated protein, mediates neuronal differentiation and protects neuroblastoma cells from nitric oxide-induced apoptosis [25]. When co-activated by glutamate-dopamine-hippocampal neurons, SCG2 is a potential regular of food intake and non-chronic body weight change by interacting with secretogranin III and accumulating appetite-related hormones into secretory granules [17]. In this study, the potential function of SCG2 in CRC tumor growth was investigated. The results showed that ectopic expression of SCG2 significantly inhibited CRC tumor growth in mice. Treatment with SCG2 protein had a therapeutic effect on CRC tumor growth. However, further studies are needed to determine the potential therapeutic effects on patient-derived in addition to CRC cell-based xenograft.

The results of the present study demonstrated an inhibitory role of SCG2 in tumor angiogenesis, which is inconsistent with the findings of previous studies [19, 18]. In both diabetic and burn wounds after fasting, expression of SCG2 was increased in endothelial cells [18]. Knockdown of SCG2 in endothelial cells markedly attenuated the fasting/refeeding-induced pro-angiogenic effects [18]. Furthermore, treatment of human ovarian microvascular endothelial cells with secretoneurin, the cleaved bioactive peptide of SCG2, significantly promoted ovarian angiogenesis by increasing endothelial cell migration [19]. In this study, the regulatory role of SCG2 in tumor angiogenesis in relation to cytokine excretion by tumor cells was investigated rather than solely focusing on the direct role of SCG in endothelial cells. The results revealed that ectopic expression of SCG2 in tumor cells significantly inhibited tumor angiogenesis in mice. Treatment with conditioned medium efficiently blocked the migration and sprouting of HUVECs. The opposite role of SCG2 in angiogenesis demonstrated in the present and previous studies [19, 18] could be due to the use of different cell types. Nonetheless, the results of the present study provide multiple angles of evidence of the role of SCG2 in angiogenesis.

To clarify the molecular mechanism underlying the inhibitory effect of SCG2 on tumor angiogenesis, transcriptional profiling indicated that VEGF, which as a promoter of angiogenesis
and defined as a therapeutic target of tumor angiogenesis [26, 27, 10], was inhibited by SCG2 in cancer cells. Rescuing of VEGF in conditioned medium from SCG-overexpressed cells efficiently blocked the SCG2-induced inhibition of tumor angiogenesis. The results of this study also showed that expression of VEGF was inhibited by SCG2 at the mRNA and protein level, suggesting that SCG2 inhibits expression of VEGF at the transcriptional level. However, the location of SCG2 in the cytoplasm indicated that SCG2 may inhibit the transcription of VEGF by regulating the expression of transcription factors, such as HIF-1 [28-30]. Also, SCG2 inhibited expression of HIF-1α in cancer cells by interacting with VHL, a ubiquity-degrading enzyme of HIF-1α [31-33]. But, expression of VHL was not regulated by SCG2 in cancer cells, suggesting that SCG2 may promote the role of HIF-1α in ubiquity degradation via binding VHL. Therefore, further studies are needed to clarify the mechanisms underlying this process.

5. Conclusion

In summary, the results of this study clarified the function and mechanism of SCG2 in the regulation CRC tumor growth, which may provide a potential therapeutic target and a prognostic predictor. The identified role of SCG2 in tumor angiogenesis provided multiple angles of evidence of the role of SCG2 in angiogenesis. However, further studies are required to determine the potential role of SCG2 in CRC carcinogenesis in conditional knockout mice.

Acknowledgements

The relevant institutional Ethics Committees approved this study. The author(s) indicate no potential conflicts of interest. This work was supported by Research Foundation of Health Commission of Sichuan Province (Grant No.19PJ102), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant No. ZY2016105), Post-Doctor Research Project, West China Hospital, Sichuan University (Grant No. 2020HXBH038), and research foundation of outstanding young scholars of sichuan university (No.2016SCU04B04).

Conflict of interest:

The authors disclose no potential conflicts of interest.
Author contributions

CF, LD, and CWF were responsible for the design and conduct of experiments, analysis, interpretation of data, and graphing. CW, LY, and YYY provided the survival data. CF drafted the manuscript. All authors read and approved the final manuscript. HXD and ZGZ supervised the whole analysis and provided guidance and instructions.

Consent for publication

Consent to publish has been obtained from all authors.

Data availability statement

All data in our study are available upon request.

Reference

1. Siegel RL, Miller KD & Jemal A (2019) Cancer statistics, 2019. CA: a cancer journal for clinicians 69, 7-34, doi: 10.3322/caac.21551.

2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B & Starling N (2010) Colorectal cancer. Lancet (London, England) 375, 1030-1047, doi: 10.1016/s0140-6736(10)60353-4.

3. Osumi H, Shinozaki E, Yamaguchi K & Zembutsu H (2019) Clinical utility of circulating tumor DNA for colorectal cancer. Cancer science 110, 1148-1155, doi: 10.1111/cas.13972.

4. Thanikachalam K & Khan G (2019) Colorectal Cancer and Nutrition. Nutrients 11, doi: 10.3390/nu11010164.

5. Jideh B & Bourke MJ (2018) Colorectal cancer screening reduces incidence, mortality and morbidity. The Medical journal of Australia 208, 483-484.

6. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C & Negri E (2018) European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 29, 1016-1022, doi: 10.1093/annonc/mdy033.

7. Siegel R, Desantis C & Jemal A (2014) Colorectal cancer statistics, 2014. CA: a cancer journal for clinicians 64, 104-117, doi: 10.3322/caac.21220.

Molecular Oncology (2020) © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
8. Mody K & Bekaii-Saab T (2018) Clinical Trials and Progress in Metastatic Colon Cancer. Surgical oncology clinics of North America 27, 349-365, doi: 10.1016/j.soc.2017.11.008.

9. Nappi A, Berretta M, Romano C, Tafuto S, Cassata A, Casaretti R, Silvestro L, Divitiis C, Alessandrini L, Fiorica F, Ottaiano A & Nasti G (2018) Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives. Current cancer drug targets 18, 421-429, doi: 10.2174/1568009617666170209095143.

10. Viallard C & Larrière B (2017) Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis 20, 409-426, doi: 10.1007/s10456-017-9562-9.

11. Krishna Priya S, Nagare RP, Sneha VS, Sidhanth C, Bindhya S, Manasa P & Ganesan TS (2016) Tumour angiogenesis-Origin of blood vessels. International journal of cancer 139, 729-735, doi: 10.1002/ijc.30067.

12. Vallée A, Guillevin R & Vallée JN (2018) Vasculogenesis and angiogenesis initiation under normoxic conditions through Wnt/β-catenin pathway in gliomas. Reviews in the neurosciences 29, 71-91, doi: 10.1515/revneuro-2017-0032.

13. Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlonmagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G & Falcone A (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. The Lancet Oncology 16, 1306-1315, doi: 10.1016/s1470-2045(15)00122-9.

14. Itatani Y, Kawada K, Yamamoto T & Sakai Y (2018) Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. International journal of molecular sciences 19, doi: 10.3390/ijms19041232.

15. Rahbari NN, Kedrin D, Incio J, Liu H, Ho WW, Nia HT, Edrich CM, Jung K, Daubriac J, Chen I, Heishi T, Martin JD, Huang Y, Maimon N, Reissfelder C, Weitz J, Boucher Y, Clark JW, Grodzinsky AJ, Duda DG, Jain RK & Fukumura D (2016) Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Science translational medicine 8, 360ra135, doi: 10.1126/scitranslmed.aaf5219.

16. Berard AR, Severini A & Coombs KM (2015) Differential Reovirus-Specific and Herpesvirus-Specific Activator Protein 1 Activation of Secretogranin II Leads to Altered Virus Secretion. Journal of virology 89, 11954-11964, doi: 10.1128/jvi.01639-15.

17. Hotta K, Hosaka M, Tanabe A & Takeuchi T (2009) Secretogranin II binds to secretogranin III and forms
secretory granules with orexin, neuropeptide Y, and POMC. The Journal of endocrinology 202, 111-121, doi: 10.1677/joe-08-0531.

18. Luo MJ, Rao SS, Tan YJ, Yin H, Hu XK, Zhang Y, Liu YW, Yue T, Chen LJ, Li L, Huang YR, Qian YX, Liu ZZ, Cao J, Wang ZX, Luo ZW, Wang YY, Xia K, Tang SY, Chen CY & Xie H (2020) Fasting before or after wound injury accelerates wound healing through the activation of pro-angiogenic SMOC1 and SCG2. Theranostics 10, 3779-3792, doi: 10.7150/thno.44115.

19. Hannon PR, Duffy DM, Rosewell KL, Brännström M, Akin JW & Curry TE, Jr. (2018) Ovulatory Induction of SCG2 in Human, Nonhuman Primate, and Rodent Granulosa Cells Stimulates Ovarian Angiogenesis. Endocrinology 159, 2447-2458, doi: 10.1210/en.2018-00020.

20. Alrawashdeh W, Jones R, Dumartin L, Radon TP, Cutillas PR, Feakins RM, Dmitrovic B, Demir IE, Ceyhan GO & Crnogorac-Jurcevic T (2019) Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling. Molecular oncology 13, 1075-1091, doi: 10.1002/1878-0261.12463.

21. Liu JW, Yu F, Tan YF, Huo JP, Liu Z, Wang XJ & Li JM (2020) Profiling of Tumor Microenvironment Components Identifies Five Stroma-Related Genes with Prognostic Implications in Colorectal Cancer. Cancer biotherapy & radiopharmaceuticals, doi: 10.1089/cbr.2020.4118.

22. Sun G, Li Y, Peng Y, Lu D, Zhang F, Cui X, Zhang Q & Li Z (2019) Identification of a five-gene signature with prognostic value in colorectal cancer. Journal of cellular physiology 234, 3829-3836, doi: 10.1002/jcp.27154.

23. Jiang Q, Dai L, Chen N, Li J, Gao Y, Zhao J, Ding L, Xie C, Yi X, Deng H & Wang X (2020) Integrative analysis provides multi-omics evidence for the pathogenesis of placenta percreta. Journal of cellular and molecular medicine, doi: 10.1111/jcmm.15973.

24. Du HL, Chen J, Zhang YS & Zhang XQ (2008) Molecular cloning, mapping, and polymorphism of the porcine SCG2 gene. Biochemical genetics 46, 369-379, doi: 10.1007/s10528-008-9153-y.

25. Kim HJ, Denli AM, Wright R, Baul TD, Clemenson GD, Morcos AS, Zhao C, Schafer ST, Gage FH & Kagalwala MN (2015) REST Regulates Non-Cell-Autonomous Neuronal Differentiation and Maturation of Neural Progenitor Cells via Secretogranin II. The Journal of neuroscience : the official journal of the Society for Neuroscience 35, 14872-14884, doi: 10.1523/jneurosci.4286-14.2015.

26. Apte RS, Chen DS & Ferrara N (2019) VEGF in Signaling and Disease: Beyond Discovery and Development. Cell 176, 1248-1264, doi: 10.1016/j.cell.2019.01.021.
27. Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, Moldovan IM, Roman AL & Mihu CM (2018) Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 59, 455-467.

28. Dai L, Cui X, Zhang X, Cheng L, Liu Y, Yang Y, Fan P, Wang Q, Lin Y, Zhang J, Li C, Mao Y, Wang Q, Su X, Zhang S, Peng Y, Yang H, Hu X, Yang J, Huang M, Xiang R, Yu D, Zhou Z, Wei Y & Deng H (2016) SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin. Nature communications 7, 11996, doi: 10.1038/ncomms11996.

29. Harris AL (2002) Hypoxia--a key regulatory factor in tumour growth. Nature reviews Cancer 2, 38-47, doi: 10.1038/nrc704.

30. Zimna A & Kurpisz M (2015) Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies. BioMed research international 2015, 549412, doi: 10.1155/2015/549412.

31. Fallah J & Rini BI (2019) HIF Inhibitors: Status of Current Clinical Development. Current oncology reports 21, 6, doi: 10.1007/s11912-019-0752-z.

32. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER & Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275, doi: 10.1038/20459.

33. Shen C & Kaelin WG, Jr. (2013) The VHL/HIF axis in clear cell renal carcinoma. Seminars in cancer biology 23, 18-25, doi: 10.1016/j.semcancer.2012.06.001.

Figure legends

Figure 1. Downregulation of SCG2 is correlated with poor prognosis of CRC patients. (A) IHC staining of SCG2 expression in CRC tissues and normal colorectal tissues (n=115). Scale bar = 100 μm. (B) Analysis of SCG2 expression in 115 paired CRC tissues (t test). (C) Analysis of SCG2 expression in 46 normal colorectal tissues and 155 CRC malignant tissues from the TCGA-COAD database (t test). (D and E) Log-rank test of disease free survival (D) and overall survival (E) of CRC patients with high Vs low SCG2 expression based on IHC staining in the HXCRC cohort (Log-rank Test).
Figure 2. SCG2 impairs CRC tumor growth. (A) Proteins were extracted from CRC cells and human intestinal epithelial cells for western blot analysis. (B) SW620 and RKO cells were stably infected with lenti-control (Ctrl) and a SCG2 overexpression system. Proteins were extracted from SW620-Ctrl, SW620-SCG2, RKO-Ctrl, and RKO-SCG2 cells for western blot analysis. (C) IHC staining of SCG2 expression in SW620-Ctrl and SW620-SCG2 tumors. Scale bar = 100 μm. Analysis of SCG2-positive cells in SW620 tumors (n=4, ** p<0.01, mean ± SD, t test). (D) Images of SW620-Ctrl and SW620-SCG2 tumors. (E) At 10 days post-injection, the SW620-Ctrl and SW620-SCG2 tumor length and width were measured every 3 days and a tumor growth curve was generated (n=5, ** p<0.01, mean ± SD, t test). (F) Analysis of SW620-Ctrl and SW620-SCG2 tumor weights (n=5, **, p<0.01, mean ± SD, t test). (G) Images of RKO-Ctrl and RKO-SCG2 tumors. (H) At 10 days post-injection, the RKO-Ctrl and RKO-SCG2 tumor length and width were measured every 3 days and a tumor growth curve was generated (n=5, ** p<0.01, mean ± SD, t test). (I) Analysis of RKO-Ctrl and RKO-SCG2 tumor weights (n=5, ** p<0.01, mean ± SD, t test).

Figure 3. SCG2 inhibits angiogenesis in CRC. (A) IHC staining of CD31 in SW620-Ctrl and SW620-SCG2 tumors (n=4). Scale bar = 100 μm. (B and C) Analysis of vessel density (B) and area (C) in SW620-Ctrl and SW620-SCG2 tumors (n=4, ** p<0.01, mean ± SD, t test). (D) IHC staining of CD31 in RKO-Ctrl and RKO-SCG2 tumors (n=4). Scale bar = 100 μm. (E and F) Analysis of vessel density (E) and area (F) in RKO-Ctrl and RKO-SCG2 tumors (n=4, ** p<0.01, mean ± SD, t test). (G) IHC staining of CD31 in SW620-Ctrl and SW620-SCG2 Matrigel-based plug assay (MPA) (n=4). Scale bar = 100 μm. (H and I) Analysis of vessel density (H) and area (I) in SW620-Ctrl and SW620-SCG2 MPA (n=4, ** p<0.01, mean ± SD, t test). (J and K) The supernatants of the indicated cultured cells were collected and used as conditioned medium for HUVEC tube formation. The number of branch points per frame was counted and analyzed (n=4, ** p<0.01, mean ± SD, t test). Scale bar = 100 μm. (L and M) The supernatant of the indicated cultured cells were collected and used as conditioned medium for the HUVEC invasion assay. The number of invaded cells per frame was counted and analyzed (n=4, ** p<0.01, mean ± SD t test). Scale bar = 100 μm.

Figure 4. SCG2 inhibits angiogenesis via downregulating VEGF expression. (A) Sequencing of coding RNA in SW620-Ctrl and SW620-SCG2 tumors. (B) KEGG analysis of deregulated coding RNA between SW620-Ctrl and SW620-SCG2 tumors. (C) qPCR analysis of VEGF mRNA
expression in the indicated tumors (n=3, ** p<0.01, mean ± SD, t test). (D) IHC staining of VEGF expression in SW620-Ctrl and SW620-SCG2 tumors. Scale bar = 100 μm. Analysis of VEGF-positive cells in SW620 tumors (n=4, ** p<0.01, mean ± SD, t test). (E) qPCR analysis of VEGF mRNA expression in the indicated cells (n=3, ** p<0.01, mean ± SD, t test). (F) Proteins of the indicated cells were extracted for western blot analysis. (G) The cell culture supernatants of indicated cells were collected for use in an ELISA (n=3, ** p<0.01, mean ± SD, t test). (H and I) VEGF protein was added to the cell culture supernatant of SW620-SCG2 cells to rescue VEGF expression. The conditioned medium was used for the HUVEC tube formation assay (H) and invasion assay (I). Scale bar = 100 μm (n=3, ** p<0.01; ns, no significant difference, mean ± SD, t test).

Figure 5. SCG2 promotes HIF-1α degradation via binding to VHL. (A and B) Proteins of the indicated cells were extracted for western blot analysis. (C) The indicated cells were treated with MG132. After 4 h, proteins were extracted for western blot analysis. (D) Proteins of SW620-SCG2 cells were extracted for co-immunoprecipitation analysis. The immunoprecipitated proteins were used for western blot analysis. (E) IHC staining of HIF-1α expression in SW620-Ctrl and SW620-SCG2 tumors. Scale bar = 100 μm. Analysis of HIF-1α positive cells in SW620 tumors (n=4, ** p<0.01, mean ± SD, t test). (F and G) The indicated cells were treated with DMOG. After 24 h, proteins were extracted for western blot analysis (F) and the cell culture supernatant was collected for use in an ELISA (G, n=3, ** p<0.01, mean ± SD, t test).

Figure 6. Inverse correlation between SCG2 and HIF-1α/VEGF in CRC tissues. (A) IHC staining of SCG2, HIF-1α and VEGF expression in 45 CRC malignant tissues. Scale bar = 100 μm. (B) Correlation analysis of SCG2 positive cells and HIF-1α positive cells in 45 CRC malignant tissues (n=45, pearson’s χ² test). (C) Correlation analysis of SCG2 positive cells and VEGF positive cells in 45 CRC malignant tissues (n=45, pearson’s χ² test).

Figure 7. SCG2 protein inhibits CRC tumor growth in mice. (A) IgG and SCG2 (10 μg/mice/time) were injected into the tumors at 8, 10 and 12 days post SW620 cell injection. (B) Image of SW620 tumors treated with IgG or SCG2 protein. (C) At 8 days post-injection, the SW620 tumor length and width were measured every 3 days and a tumor growth curve was generated (n=5, ** p<0.01, mean ± SD, t test). (D) Analysis of SW620-IgG and SW620-SCG2 tumor weights (n=5, ** p<0.01, mean ± SD, t test). (E-G) IHC staining of SCG2 (E), HIF-1α (F), and VEGF (G) expression in SW620-IgG and SW620-SCG2 tumors (n=4). Scale bar = 100 μm.
Analysis of SCG2-, HIF-1α- and VEGF-positive cells in SW620 tumors (n=4, ** p<0.01, mean ± SD, t test).

Support information

Supplementary Figure 1 Legends. SCG2, HIF-1α, VHL and hydroxyl-HIF-1α expression under hypoxia. (A) Proteins of the indicated cells after hypoxia exposure were extracted for western blot analysis. (B and C) The supernatants of the indicated cultured cells after hypoxia exposure were collected and used as conditioned medium for HUVEC tube formation. The number of branch points per frame was counted and analyzed (n=4, ** p<0.01). (D and E) The supernatant of the indicated cultured cells after hypoxia exposure were collected and used as conditioned medium for the HUVEC invasion assay. The number of invaded cells per frame was counted and analyzed (n=4, ** p<0.01).
A

B

C

D

E

F

G

H

I

mol2_13044_f2.jpg
mol2_13044_f3.jpg
mol2_13044_f4.jpg
